(Q37843715)

24 August 2017

1 reference

title

Current and future treatment options in osteoporosis (English)

1 reference

24 August 2017

0 references

Linda Brewer

1

1 reference

24 August 2017

David Williams

series ordinal

2

1 reference

24 August 2017

Alan Moore

series ordinal

3

1 reference

24 August 2017

publication date

16 February 2011

1 reference

European Journal of Clinical Pharmacology

24 August 2017

published in

1 reference

24 August 2017

volume

67

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

321-331

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

24 August 2017

1 reference

Epidemiology and outcomes of osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

FRAX and the assessment of fracture probability in men and women from the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

The cost-effectiveness of strontium ranelate in the UK for the management of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Optimal vitamin D status for the prevention and treatment of osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Calcium plus vitamin D supplementation and the risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Therapy of osteoporosis with calcium and vitamin D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Reports of esophageal cancer with oral bisphosphonate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Exposure to oral bisphosphonates and risk of esophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Lasofoxifene in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Denosumab in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Osteonecrosis of the jaw in a patient on Denosumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Osteonecrosis of the jaws induced by anti-RANK ligand therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Effect of the cathepsin K inhibitor odanacatib on bone resorption biomarkers in healthy postmenopausal women: two double-blind, randomized, placebo-controlled phase I studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

The effect of teriparatide on serum Dickkopf-1 levels in postmenopausal women with established osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Bone mass is inversely proportional to Dkk1 levels in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

The effect of intramuscular vitamin D (cholecalciferol) on serum 25OH vitamin D levels in older female acute hospital admissions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

The effect of raloxifene treatment in postmenopausal women with CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Effects of short-term alendronate on bone mineral density in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Developments in the scientific understanding of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Development and use of FRAX in osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Alendronate Treatment in Women With Normal to Severely Impaired Renal Function: An Analysis of the Fracture Intervention Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Disassociation of bone resorption and formation by GLP-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Four-month treatment with GLP-2 significantly increases hip BMD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00228-011-0999-2

Denosumab: an investigational drug for the management of postmenopausal osteoporosis

21 January 2018

1 reference

12 December 2020

A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study

1 reference

12 December 2020

Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety

1 reference

12 December 2020

Remodeling and skeletal fragility

1 reference

12 December 2020

Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI

1 reference

12 December 2020

The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis

1 reference

12 December 2020

Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

1 reference

12 December 2020

Treatment of reduced bone density with ibandronate in dialysis patients

1 reference

12 December 2020

Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women

1 reference

12 December 2020

Wnt signaling as a therapeutic target for bone diseases

1 reference

12 December 2020

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density

1 reference

12 December 2020

10.1007/S00228-011-0999-2

Identifiers

DOI

1 reference

release_bohroat72rautkp542zm6njr64

24 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bohroat72rautkp542zm6njr64

24 November 2022

mapped directly with Wikidata item

1 reference